Applied BioCode — Investor Presentation 2026

May 13, 2026

Applied BioCode
Barcoded Magnetic Beads | Highly Multiplex Assays

Applied BioCode Corporation

ABC-KY (6598)

Digital Precision Medicine Platform With FDA Clearance

May 14th, 2026

http://www.apbiocode.com/

---

Symbol : ABC-KY
6598

Disclaimer

• This presentation contains predictive information including operational information, financial information, and sales information, based on internal and external sources.
• This presentation covers prospect based on company’s current point of view, meaning change and adjustment may occur over time, and the company is not responsible to disclose such change upon occurrence.
• The company’s future actual operational and financial results may be impacted by material risks and other causes, therefore differ from current prediction. The company claims that this presentation is only for informational purpose, not recommendation of investment. The company is not responsible for any one’s harm due to the use of this presentation.

Confidential
Applied BioCode

---

Applied BioCode Corporation (ABC-KY, 6598)

IVD Company in High Growth Phase

Serving Human and Animal Diagnostics

TWSE IPO : 2020.6.9 Founder: Winston Z. Ho Ph.D

Business Area : Develop, Manufacture, Sales of

Diagnostics Products

Headquarters: US & TW Employees : 80

Capital: $1BTWD

2026 Q1 Highlight

81% Revenue growth.
2.2E TWD Historical high

50% Sales growth in US labs.

130% Sales growth in animal market.

159% Net income increase rate. Turns positive.

2026 Momentum

• US lab customers shifting towards FDA cleared products due to tighter reimbursement control on LDT.
• Partnering with Thermo Fisher extraction systems for quick market adaption.
• Animal market partner expanding usage, release $11MUSD order.

Core Competency

Platform Original from Taiwan Semiconductor Fab Process

BMB platform 70um x 35um

• First TW based platform to receive US-FDA clearance.
• Unlike other chip based solution, BMB is flexible to add new markers and scale up.

Own brand + US Channel

Highly experienced in obtaining US Premarket Clearance and Reimbursement Codes.

IVD US Market

• Target 600 Labs Million $$ Account
• Established 5 sales & service regional offices.

Animal Health

Licensing to dominant pet diagnostics leader. Commercialized serum, fecal, and lymphoma panels.

BMB Applications

Application Market is up to $80BUSD, including infectious disease, oncology, autoimmune, industrial and agricultural applications.

Confidential

---

Symbol : ABC-KY
6598

Corporate Structure

ABC-KY: 6598
Taiwan Stock Exchange
Listed
Capital
1,028,190,210TWD

100%

Applied BioCode, Inc
(Los Angeles)
Multiplex IVD products
design, manufacture, and
sales

100%

Applied BioCode Taiwan Ltd.
(Taipei)
Manufacture of Barcoded
Magnetic Beads

Applied BioCode
Confidential

---

Symbol : ABC-KY
6598

Experienced Leadership Team

• George J. Lee, Ph.D., Co-Founder, Chairman
  Dr.Lee was previously Chairman of Epitomics, Inc. (acquired by Abcam Ltd.). Served as Director in various successfully IPO companies in Taiwan, including Foresee Pharmaceuticals and Crown Bioscience (acquired by JSR with 104% capital premium) Served as Director in Renal Solution (acquired by Fresenius Medical Care) • Director in Panomics, Inc. (acquired by Affymetrics) and TP Therapeutics (NASDAQ,: TPTX) • Dr.Lee received Ph.D. of Biochemistry in State University of New York, Buffalo.

• Winston Z. Ho, Ph.D., Co-Founder, CEO
  Dr.Ho was founder and CEO of Maxwell Sensors. Served as Head of sensor department in Intelligent Optical Systems. Published 52 journals and received 15 patents. Accumulated over $10MUSD research grant. Served as NIH and SPIE grant review committee. Received Master of Biochemistry then Ph.D. of Biophysics in Arizona State University, Post-doc in Columbia University, and research fellow in Arizona Optical Science Center.

• Beth Laderman, Ph.D., CSO
  Previously HYCOR Biomedical CSO.
  Biomerica VP of Product Development
  Focus Diagnostics Head of Immunoassay

• Jim Leigh, VP of Sales
  Previously Renovia, Inc VP of Account management
  Hologic, Inc Director of Account management

• Parisa Hanachi, Ph.D., VP of Marketing
  Previously Abbott Infectious Diagnostics Department
  Chief Marketing Officer
  Roche Diagnostic Senior Marketing Director.
  ThermoFisher Product Manager

• Anami Patel, Ph.D. MB, Director of Clinical Affair
  Previously Poplar Heath Lab Director

Applied BioCode
Confidential

---

Confidential
Applied BioCode

Recent Operational Highlights

---

Q1 US Lab Market Propels Strong Growth 50%

Gain traction in national reference labs

Million USD
Q1 US IVD Sales Growth

Million USD
Human Business Growth
w/o Covid

Applied BioCode

---

Q1 Animal Health Partner Scaling Up BMB 130%

Q1 Animal Business Growth

Previous Trend

Applied BioCode

---

2026 Q1 Growth

Both IVD and Pet Market Uptick

2026Q1 revenue $2.2E TWD, 81% growth yoy. ($6.9MUSD, 88% growth yoy)

GM64.6% EPS0.2 TWD

Q1 Net Income increase rate 159%

Animal health related order $11MSUD.

IVD demand is stable, though RPP sees higher demand in flu seasons, and GPP sees higher demand in Spring/Summer.

Applied BioCode

---

Confidential
Applied BioCode

Products and Technology

---

Comprehensive Infectious Dx Pipeline

Symbol: ABC-KY 6598

Comprehensive Pipeline · Over 100 Targets · on single MDx3000

2019	2020	2021	2022	2023	2024	2025	2026
MDx3000	20 plex RPP	SARS-Cov-2	7-in-1
Cov-Flu-Plus	20 plex
Fungal RUO	GPP + KingFisher	Semi-Automation	UTI
17 plex GPP	SARS-Cov-2 pooling			13 plex
STI+AMR	RPP + KingFisher

Applied BioCode

---

SD 100000000000000000000000000000000000000000000000000000000000000000000

SD 100000000000000000000000000000000000000000000000000000000000

SD 10000000000000000000000000000000000000000000

SD 10000000000000000000000000000000000000000000000

SD 1000000000000000000000000000000000000000000

SD

MDx3000 Best Choice for High Volume Labs

Symbol: ABC-KY 6598

The only FDA approved, automated, high volume, multiplex platform in market

• 96 samples in 3.5 hours to report
• Minimum manual operations, load samples in 10 mins, then walk away
• Can simultaneously run different sample types (GPP、RPP、Fungal、STI、UTI...)
• Masking Feature, Flexible Reporting, satisfy reimbursement needs
• Flexibility---FDA approves 3 different DNA Extraction front end instruments.

Applied BioCide

---

Symbol : ABC-KY
6598

Multiplex Capability is highly coveted Asset

Diagnostics is constantly consolidating, ABC being a beneficiary

Confidential
Applied BioCode

---

Symbol : ABC-KY 6598

Infectious Dx is Largest MDx Sector

MDx Diagnostics fastest growing methodology

INFECTIONOUS DISEASE DIAGNOSTICS TYPE

First targeting N.America

Occupied Tier 1 customer such as S Lab, L Lab, Q Lab, Baylor, Johns Hopkins...

Up to 600 reference labs and core labs

Confidential

Applied BioCode

---

Symbol : ABC-KY
6598

BMB offers Unparallel Bio-Identification

• Proprietary digital Bio-Barcode platform: Barcoded magnetic Beads (BMB)
• Miniature micro digital barcode (1,000,000x smaller) to identify Biomarkers.
• One platform for protein and DNA assay, long stability, easily scalable via semiconductor processing, 100x cheaper than bio-chip.

Dimension: 1.5 in x 0.5 inch
Material: paper

Barcode scanner

Dimension: 70 μm x 35 μm
Material: Biopolymer
Variety: 4,096 different com

Microscopic Scanner

Protein Multiplex Assay

Confidential
Applied BioCode

---

Symbol : ABC-KY
6598

Generate Meaningful Big Data

Digital method, single fluorescence provides high multiplex results in seconds.

White Field Image

Fluorescent Image

Applied BioCode

---

Symbol : ABC-KY
6598

Platform Comparison

	Luminex	Applied Biocode
Technology Type	Analog Color	Digital Barcode ☑
Associate Instrument	xMAP	MDx3000
Reagent kits	GI, RVP	GI, RPP, Fungal, STD ☑
Run Time	5-6 hours	3.5 hours ☑
Automated	N	Y ☑
Max Targets per test	300	4096 ☑
Obtained FDA	Y	Y
Weakness	Microfluidic channel clogging, cross contamination prone to customer complaint	Later to market

Applied BioCode

---

Symbol : ABC-KY 6598

80BUSD Application Market

• Can be used for both immunoassay and molecular diagnostics applications
• ABC IVD Reagent focus on infectious disease, other applications via cooperations.

IVD and Precision Medicine

• Infectious Disease
• Personal Medicine
• Cancer Diagnostics
• Companion Diagnostics
• Autoimmune Disease
• Blood culture
• Allergy

Life Science

• Biomarker Discovery
• Cytokine Test
• Protein Expression
• Fusion gene mutation
• Point mutation

Industrial Use

• Animal, Agriculture
• Bio-Defense
• Cattle infectious disease
• Food safety
• Pharmaceutical QC

Applied BioCode

---

Symbol : ABC-KY
6598

New Application – BMB Liquid Biopsy

• Identify ctDNA from blood sample
• Minimum Residual Disease market
• Instrument validated with real sample
• Identify 50 gene mutations at once
• High Sensitivity comparable to NGS
• No sequencing needed
• Lower social burden

Applied BioCode
Confidential
19

---

Symbol : ABC-KY
6598

BMB Liquid Biopsy with Disruptive Potential

US MRD insurance payment is currently ~$2000USD

NGS is hard to afford. But BMB based LB targets ~50 actionable biomarkers to provide most simultaneous, trackable, and affordable solution.

Method	Mutations	Sensitivity (ctDNA/cfDNA)	Turn Around Time	Labor	Price per Sample (USD)
NGS Sequencing	200-700 (overkill)	0.5~5%	7-21 days	Intensive	$1,500-$5,000*
ABC BMB-LB	10 – 50	Same	4-6 hours	Low	$100-$300

*: The Journal of Molecular Diagnostics, V.25, No.1,Jan. 2023

20
Applied BioCode